Post Profile






Targeting estrogen receptor improves progression-free survival in advanced breast cancer

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, rese...

Clinical Trial at MD Anderson Cancer Center Orlando Testing New Oral Medication to Treat Breast Cancer

Health : Newswise Medical News

MD Anderson Cancer Center Orlando is participating in a clinical trial to evaluate a new oral medication (BKM120) in combination with Fulvestrant to treat locally advanced or metastatic breast cancer that is hormone receptor positiv...

Researchers discover new hormone receptors to target when treating breast cancer

Health : Medical News Today

About three-quarters of breast cancers, the most common cancer in women in the U.S., are estrogen hormone dependent. Patients with this type of breast cancer are initially treated with drugs that block estrogen, such as Tamoxifen. H...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers report.

Comments


Copyright © 2016 Regator, LLC